ClinicalTrials.gg
RecruitingNCT07588100CENOTEUpdated Nov 9, 2026

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

A Phase 1 interventional study of RO7663498 in Diabetic Retinopathy, sponsored by Hoffmann-La Roche. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 13, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
134th of 196
30 · median 72
Started
2026
with 18 others
Phase 1
29 of 267
4 open now
Primary completion
2028-01
later than 34 of 52 live
Registered
259th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 134th largest by planned enrollment of the 196 interventional ones that give a count, is one of 19 that started in 2026, is one of 29 in phase 1, reaches primary completion later than 34 of the 52 other live ones, and was the 259th registered.

Diabetic Retinopathy

781 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, and pharmacokinetics (PK) of intravitreal (IVT) injections of RO7663498 in participants with diabetic retinopathy (DR).

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion Criteria

  • Diagnosis of Diabetes Mellitus (DM) (Type 1 or Type 2), as defined by the World Health Organization and/or American Diabetes Association

Ocular Inclusion Criteria for the Study Eye

  • BCVA score at screening of >= 19 letters in study eye using Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity testing charts
  • Non-proliferative diabetic retinopathy (NPDR) as assessed by the investigator and confirmed by the Central reading center (CRC)
  • Collection of >= 90 micro liter (μL) AH deemed feasible and safe by the investigator.

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria:

  • Any known to any of the following compounds: fluorescein; any dilating, anesthetic, or povidone iodine eye drops; or any contained in the treatments used in this study.
  • History of hypersensitivity to biologic agents, the drug, or any of the excipients contained in the formulation administered IVT or systemically.

Ocular Exclusion Criteria for the Study Eye

  • Center-involved Diabetic Macular Edema (DME)
  • Any history or concurrent ocular conditions/procedures and/or visual system conditions of the below.
  • Vitreoretinal surgery/pars plana vitrectomy.
  • Any history of glaucoma surgery or planned glaucoma surgery during the study.
  • Uncontrolled glaucoma
  • Anterior segment neovascularization.
  • Vitreous or preretinal hemorrhage.
  • Any ocular disease other than DR and DME that may Confound assessment of the retina in the opinion of the investigator or Confound development of worsening DR, DME, or retinal nonperfusion.
  • Any presence of active intraocular inflammation on Day 1 (i.e., Standardization of Uveitis Nomenclature [SUN] criteria > 0 or National Eye Institute [NEI] vitreous haze grading > 0) or any history of IOI.
  • Aphakia or previous violation of the posterior capsule in the study eye

Ocular Exclusion Criteria for the Non-study Eye

  • BCVA \< 38 letters
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Participants will receive RO7663498.

    Drug: RO7663498

  • Experimental
    Cohort 2

    Participants will receive RO7663498.

    Drug: RO7663498

  • Experimental
    Cohort 3

    Participants will receive RO7663498.

    Drug: RO7663498

  • Experimental
    Cohort 4

    Participants will receive RO7663498.

    Drug: RO7663498

Interventions

  • DrugRO7663498

    Participants will receive RO7663498 as per the schedule defined in the protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Ocular Adverse Events (AEs)

    Time frame: Up to Week 20

  2. Percentage of Participants With Systemic (non-ocular) AEs

    Time frame: Up to Week 20

  3. Number of Abnormalities Recorded in Standard Ophthalmological Assessments

    Time frame: Up to Week 20

Secondary outcomes

  1. Aqueous Humor (AH) Concentrations of RO7663498

    Time frame: Up to Week 12

  2. Serum Concentrations of RO7663498

    Time frame: Up to Week 20

07

Study locations

4 of 4 sites recruiting
  • Global Research Management
    Glendale, California 91204, United States
    Recruiting
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
    Recruiting
  • Ohio State Havener Eye Institute;Ophthalmology Research
    Columbus, Ohio 43212, United States
    Recruiting
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
    Recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 14, 2026
StartActual
Jun 18, 2026
Primary completionEst.
Jan 20, 2028
CompletionEst.
Jan 20, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Medical Center Ophthalmology Associates · San Antonio, United States
Oct 13, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 13, 2026
    1 site added
    Show site
    • Medical Center Ophthalmology Associates · San Antonio, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07588100
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Jun 18, 2026
Primary completion
Jan 20, 2028 (estimated)
Completion
Jan 20, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Reference Study ID Number: BP46156 https://forpatients.roche.com/ No email attachments.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion